RxDoctor Payments Data

Ravinderpal Gill, MD

Internal Medicine · Demorest, GANPI 1992071096

Payments from drug & device makers

$1,774in general payments, 2019–2025

Across 103 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$330
  • Novo Nordisk$300
  • GSK$167
  • Corcept Therapeutics$158
  • Otsuka America Pharmaceutical, Inc.$134
  • Novartis$124
  • plus $561 from 10 others

What the payments were for

  • Food & beverage$1,774100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,774 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$107,091
Medicare patients
66
Services billed
2,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide96$131,881
OzempicSemaglutide38$45,809
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$42,264
EliquisApixaban60$39,041
TrulicityDulaglutide36$37,671
RybelsusSemaglutide34$35,226
JardianceEmpagliflozin15$24,648
FarxigaDapagliflozin Propanediol13$13,911
LinzessLinaclotide18$9,978
Spiriva HandihalerTiotropium Bromide13$7,797
Tresiba Flextouch U-100Insulin Degludec13$7,631
TradjentaLinagliptin13$7,202
XareltoRivaroxaban12$7,095
Dexlansoprazole DrDexlansoprazole37$6,672
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt19$6,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$75$169,552132 claims
Novo NordiskOzempic, Rybelsus$300$81,03572 claims
GSKTrelegy Ellipta$167$42,26460 claims
PfizerEliquis$62$39,04160 claims
AstraZenecaFarxiga$115$13,91113 claims
AbbVieLinzess$330$9,97818 claims
Johnson & JohnsonXarelto$25$7,09512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Demorest

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →